List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6670056/publications.pdf Version: 2024-02-01

	66234	27345
24,252	42	106
citations	h-index	g-index
110	110	101.00
113	113	12162
docs citations	times ranked	citing authors
	24,252 citations 113 docs citations	6623424,252citationsh-index113113docs citationstimes ranked

EMIN MURAT TUZCU

#	Article	IF	CITATIONS
1	Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. New England Journal of Medicine, 2010, 363, 1597-1607.	13.9	6,189
2	Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. New England Journal of Medicine, 2011, 364, 2187-2198.	13.9	5,447
3	Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. New England Journal of Medicine, 2016, 374, 1609-1620.	13.9	3,992
4	5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet, The, 2015, 385, 2477-2484.	6.3	1,388
5	5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet, The, 2015, 385, 2485-2491.	6.3	724
6	Incidence, Predictors, and Outcomes of Aortic Regurgitation After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2013, 61, 1585-1595.	1.2	702
7	Impact of Statins on Serial Coronary Calcification During Atheroma ProgressionÂand Regression. Journal of the American College of Cardiology, 2015, 65, 1273-1282.	1.2	467
8	Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. European Heart Journal, 2015, 36, 449-456.	1.0	380
9	Staging classification of aortic stenosis based on the extent of cardiac damage. European Heart Journal, 2017, 38, 3351-3358.	1.0	364
10	Intravascular Ultrasound Evidence of Angiographically Silent Progression in Coronary Atherosclerosis Predicts Long-Term Morbidity and Mortality After Cardiac Transplantation. Journal of the American College of Cardiology, 2005, 45, 1538-1542.	1.2	251
11	Propensity-Matched Comparisons of Clinical Outcomes After Transapical or Transfemoral Transcatheter Aortic Valve Replacement. Circulation, 2015, 131, 1989-2000.	1.6	250
12	Prevalence and Outcomes of Unoperated Patients With Severe Symptomatic Mitral Regurgitation and Heart Failure. Journal of the American College of Cardiology, 2014, 63, 185-186.	1.2	239
13	Infective Endocarditis After Transcatheter Aortic Valve Implantation. Circulation, 2015, 131, 1566-1574.	1.6	227
14	Procedural Experience for Transcatheter Aortic Valve Replacement and RelationÂtoÂOutcomes. Journal of the American College of Cardiology, 2017, 70, 29-41.	1.2	226
15	Ventricular septal rupture complicating acute myocardial infarction: a contemporary review. European Heart Journal, 2014, 35, 2060-2068.	1.0	219
16	The STS-ACC Transcatheter Valve Therapy National Registry. Journal of the American College of Cardiology, 2013, 62, 1026-1034.	1.2	193
17	Long-Term Outcomes of Inoperable Patients With Aortic Stenosis Randomly Assigned to Transcatheter Aortic Valve Replacement or Standard Therapy. Circulation, 2014, 130, 1483-1492.	1.6	158
18	Effect of Tricuspid Regurgitation and the Right Heart on Survival After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	148

#	Article	IF	CITATIONS
19	Insights Into Timing, Risk Factors, and Outcomes of Stroke and Transient Ischemic Attack After Transcatheter Aortic Valve Replacement in the PARTNER Trial (Placement of Aortic Transcatheter) Tj ETQq1 1 0.7	84644 rgB	T 105 erlock
20	Influence of Transcatheter Aortic Valve Replacement Strategy and Valve Design onÂStroke After Transcatheter Aortic ValveÂReplacement. Journal of the American College of Cardiology, 2014, 63, 2101-2110.	1.2	123
21	Association Between Transcatheter Aortic Valve Replacement and Early Postprocedural Stroke. JAMA - Journal of the American Medical Association, 2019, 321, 2306.	3.8	122
22	Non-HDL Cholesterol and Triglycerides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2220-2228.	1.1	119
23	Aortic annulus and root characteristics in severe aortic stenosis due to bicuspid aortic valve and tricuspid aortic valves: Implications for transcatheter aortic valve therapies. Catheterization and Cardiovascular Interventions, 2015, 86, E88-98.	0.7	88
24	Degenerative Mitral Stenosis. Circulation, 2016, 133, 1594-1604.	1.6	81
25	Percutaneous Left Atrial Appendage Occlusion for Stroke Prophylaxis in Nonvalvular Atrial Fibrillation. JACC: Cardiovascular Interventions, 2014, 7, 296-304.	1.1	80
26	Costs of Periprocedural Complications in Patients Treated With Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2014, 7, 829-836.	1.4	76
27	Fractional Flow Reserve Compared With Intravascular Ultrasound Guidance for Optimizing Stent Deployment. Circulation, 2001, 104, 1917-1922.	1.6	73
28	Implications from neurologic assessment of brain protection for total arch replacement from a randomized trial. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 1140-1147.e11.	0.4	64
29	Relationship of Beam Angulation and Radiation Exposure in the Cardiac Catheterization Laboratory. JACC: Cardiovascular Interventions, 2014, 7, 558-566.	1.1	63
30	Spotty calcification and plaque vulnerability in vivo: frequency-domain optical coherence tomography analysis. Cardiovascular Diagnosis and Therapy, 2014, 4, 460-9.	0.7	63
31	Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. European Heart Journal, 2018, 39, 2551-2558.	1.0	61
32	Transcatheter Valve-In-Valve Implantation for Failed Balloon-Expandable Transcatheter Aortic Valves. JACC: Cardiovascular Interventions, 2012, 5, 571-577.	1.1	60
33	Measures to Reduce Radiation in a Modern Cardiac Catheterization Laboratory. Circulation: Cardiovascular Interventions, 2014, 7, 447-455.	1.4	59
34	Evaluation of Flow After Transcatheter Aortic Valve Replacement in Patients With Low-Flow Aortic Stenosis. JAMA Cardiology, 2016, 1, 584.	3.0	59
35	Atheroma Progression in Hyporesponders to Statin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 990-995.	1.1	58
36	Stroke After Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement in the PARTNER Trial. Journal of the American College of Cardiology, 2018, 72, 2415-2426.	1.2	54

#	Article	IF	CITATIONS
37	Transcatheter aortic valve replacement: current perspectives and future implications. Heart, 2015, 101, 169-177.	1.2	50
38	Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	49
39	Long-Term Mortality After Cardiac Allograft Vasculopathy. JACC: Heart Failure, 2014, 2, 281-288.	1.9	48
40	Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2423-2431.	1.1	48
41	Prognostic significance of mild aortic regurgitation in predicting mortality after transcatheter aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 783-790.	0.4	46
42	Durability Data for Bioprosthetic Surgical Aortic Valve. JAMA Cardiology, 2019, 4, 71.	3.0	46
43	Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis, 2015, 242, 490-495.	0.4	43
44	Impact of Baseline Lipoprotein and C-Reactive Protein Levels on Coronary Atheroma Regression Following High-Intensity Statin Therapy. American Journal of Cardiology, 2014, 114, 1465-1472.	0.7	42
45	Percutaneous Intervention for Myocardial Infarction After Noncardiac Surgery. Journal of the American College of Cardiology, 2016, 68, 329-338.	1.2	42
46	Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: Insights from intravascular ultrasound. Atherosclerosis, 2014, 232, 377-383.	0.4	40
47	Impact of lean six sigma process improvement methodology on cardiac catheterization laboratory efficiency. Cardiovascular Revascularization Medicine, 2016, 17, 95-101.	0.3	40
48	Frequency-Domain Optical Coherence Tomographic Analysis of Plaque Microstructures at Nonculprit Narrowings in Patients Receiving Potent Statin Therapy. American Journal of Cardiology, 2014, 114, 549-554.	0.7	37
49	Current Society of Thoracic Surgeons Model Reclassifies Mortality Risk in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e006664.	1.4	36
50	Outcomes of Transcatheter AorticÂValveÂReplacement in MixedÂAorticÂValveÂDisease. JACC: Cardiovascular Interventions, 2019, 12, 2299-2306.	1.1	36
51	High-Risk Coronary Atheroma. Journal of the American College of Cardiology, 2014, 63, 1134-1140.	1.2	32
52	Cerebrovascular Events After Cardiovascular Procedures. Journal of the American College of Cardiology, 2018, 71, 1910-1920.	1.2	32
53	In-hospital mortality and stroke after surgical aortic valve replacement: A nationwide perspective. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 571-578.e8.	0.4	31
54	Peri-procedural imaging for transcatheter mitral valve replacement. Cardiovascular Diagnosis and Therapy, 2016, 6, 144-159.	0.7	31

#	Article	IF	CITATIONS
55	Management of drug eluting stent inâ€stent restenosis: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2016, 87, 1080-1091.	0.7	28
56	Rate of Progression of Aortic Stenosis and its Impact on Outcomes in Patients With Radiation-Associated CardiacÂDisease. JACC: Cardiovascular Imaging, 2018, 11, 1072-1080.	2.3	28
57	Progression of coronary atherosclerosis in stable patients with ultrasonic features of high-risk plaques. European Heart Journal Cardiovascular Imaging, 2014, 15, 1035-1041.	0.5	25
58	Comparative meta-analysis of balloon-expandable and self-expandable valves for transcatheter aortic valve replacement. International Journal of Cardiology, 2015, 197, 87-97.	0.8	25
59	Prognostic Significance of Ischemic Mitral Regurgitation on Outcomes in Acute ST-Elevation Myocardial Infarction Managed by Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 119, 20-26.	0.7	25
60	Unilateral Access Is Safe and FacilitatesÂPeripheral Bailout DuringÂTransfemoral-Approach Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 2210-2220.	1.1	24
61	Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction. European Journal of Preventive Cardiology, 2017, 24, 373-381.	0.8	23
62	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. American Journal of Cardiology, 2016, 118, 647-655.	0.7	21
63	Novel hemodynamic index for assessment of aortic regurgitation after transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2015, 86, E174-9.	0.7	20
64	Outcomes of Patients With Ischemic Mitral Regurgitation Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 114, 1011-1017.	0.7	19
65	Relation of High-Density Lipoprotein Cholesterol:Apolipoprotein A-I Ratio to Progression of Coronary Atherosclerosis in Statin-Treated Patients. American Journal of Cardiology, 2014, 114, 681-685.	0.7	18
66	Alternative access options for transcatheter aortic valve replacement in patients with no conventional access and chest pathology. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 644-651.	0.4	17
67	Safety and efficacy of cerebral protection devices in transcatheter aortic valve replacement: A clinical end-points meta-analysis. Cardiovascular Revascularization Medicine, 2018, 19, 785-791.	0.3	17
68	Transcatheter mitral valve replacement: A frontier in cardiac intervention. Cleveland Clinic Journal of Medicine, 2016, 83, S10-S17.	0.6	16
69	Atherosclerosis Imaging. Drugs, 2004, 64, 1-7.	4.9	15
70	Length of stay and longâ€ŧerm mortality following <scp>ST</scp> elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2015, 86, S1-7.	0.7	15
71	Oral Calcium Supplements Associate With Serial Coronary Calcification. JACC: Cardiovascular Imaging, 2021, 14, 259-268.	2.3	15
72	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. European Journal of Preventive Cardiology, 2016, 23, 474-485.	0.8	12

#	Article	IF	CITATIONS
73	Coronary intravascular ultrasound: a closer view. Heart, 2010, 96, 1318-1324.	1.2	11
74	Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 2017, 89, E64-E74.	0.7	10
75	Appropriate patient selection or health care rationing? Lessons from surgical aortic valve replacement in the Placement of Aortic Transcatheter Valves I trial. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 557-568.e11.	0.4	9
76	Risk of Cerebrovascular Events in PatientsÂWith Patent Foramen Ovale andÂIntracardiac Devices. JACC: Cardiovascular Interventions, 2014, 7, 1221-1226.	1.1	8
77	Renin-Angiotensin System Antagonists in Patients Without Left Ventricular Dysfunction After Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2015, 116, 508-514.	0.7	8
78	Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis. European Journal of Preventive Cardiology, 2015, 22, 1331-1339.	0.8	7
79	Management of Symptomatic Severe Aortic Stenosis in Patient With Very Severe Chronic Obstructive Pulmonary Disease. Seminars in Thoracic and Cardiovascular Surgery, 2016, 28, 783-790.	0.4	7
80	Percutaneous Therapy for Tricuspid Regurgitation. Circulation, 2017, 135, 1815-1818.	1.6	7
81	Two-Decade Trends in the Prevalence of Atherosclerotic Risk Factors, Coronary Plaque Morphology, and Outcomes in Adults Aged â‰ # 5ÂYears Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2016, 118, 939-943.	0.7	6
82	Neurologic Events After Transcatheter Aortic Valve Replacement. Interventional Cardiology Clinics, 2015, 4, 83-93.	0.2	5
83	Postoperative Migration of an Edwards-SAPIEN XT Mitral Valve-in-Valve Treated With Direct Vision Implantation During Beating-Heart Bypass. Annals of Thoracic Surgery, 2016, 101, 1182-1185.	0.7	5
84	How Symptomatic Should a Hypertrophic Obstructive Cardiomyopathy Patient Be to Consider Alcohol Septal Ablation?. Journal of the American Heart Association, 2017, 6, .	1.6	5
85	Transcatheter aortic valve replacement: History and current indications. Cleveland Clinic Journal of Medicine, 2015, 82, S6-S10.	0.6	5
86	Plaque microstructures during metformin therapy in type 2 diabetic subjects with coronary artery disease: optical coherence tomography analysis. Cardiovascular Diagnosis and Therapy, 2021, 12, 0-0.	0.7	5
87	Transcatheter Advances in the Treatment of Adult and Congenital Valvular Heart Disease. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 52.	0.4	4
88	Comparing Coronary Atheroma Progression Rates and Coronary Events in the United States, Canada, Latin America, and Europe. American Journal of Cardiology, 2016, 118, 1616-1623.	0.7	4
89	Meta-Analysis of Usefulness of Anticoagulation After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 1612-1617.	0.7	4
90	Safety and Efficacy of Balloon Aortic Valvuloplasty Stratified by Acuity of Patient Illness. Structural Heart, 2021, 5, 520-529.	0.2	4

#	Article	IF	CITATIONS
91	Predicting paravalvular leak after balloonâ€expandable <scp>TAVR</scp> . Catheterization and Cardiovascular Interventions, 2015, 86, 152-153.	0.7	3
92	Percutaneous Direct Annuloplasty. Journal of the American College of Cardiology, 2016, 67, 2937-2940.	1.2	3
93	Frequency and factors associated with inappropriate for intervention cardiac catheterization laboratory activation. Cardiovascular Revascularization Medicine, 2016, 17, 219-224.	0.3	3
94	Non-invasive volumetric assessment of aortic atheroma: a core laboratory validation using computed tomography angiography. International Journal of Cardiovascular Imaging, 2016, 32, 121-129.	0.7	3
95	Relationship of mitral valve annulus plane and circumflexâ€right coronary artery plane: Implications for transcatheter mitral valve implantation. Catheterization and Cardiovascular Interventions, 2017, 89, 932-943.	0.7	3
96	<scp>PFO</scp> closure: End of an era or beginning of a new chapter?. Catheterization and Cardiovascular Interventions, 2017, 89, 133-134.	0.7	3
97	Outcomes of Patients with Significant Obesity Undergoing TAVR or SAVR in the Randomized PARTNER 2A Trial. Structural Heart, 2018, 2, 500-511.	0.2	3
98	Outcomes of Mild Aortic Regurgitation Afterâ€ [−] Transcatheter Aortic Valve Replacement. Structural Heart, 2021, 5, 201-207.	0.2	3
99	Resource utilization for transfemoral transcatheter aortic valve replacement: An international comparison. Catheterization and Cardiovascular Interventions, 2016, 87, 145-151.	0.7	2
100	Bioresorbable Scaffold. JACC: Cardiovascular Interventions, 2017, 10, 1230-1232.	1.1	2
101	Left main coronary arterial endothelial function and heterogenous segmental epicardial vasomotor reactivity in vivo: novel insights with intravascular ultrasonography. European Heart Journal Cardiovascular Imaging, 2014, 15, 1270-1280.	0.5	1
102	Minimizing acute kidney injury during <scp>TAVR</scp> : The Importance of Seeing the Trees and the Forest. Catheterization and Cardiovascular Interventions, 2015, 85, 1254-1255.	0.7	1
103	Safety and efficacy of transcatheter aortic valve replacement in intermediate risk patients sets the stage for contemporary trials in lower risk groups. Cardiovascular Diagnosis and Therapy, 2016, 6, 459-461.	0.7	1
104	Endâ€stage renal disease as an independent risk factor for inâ€hospital mortality after coronary drugâ€eluting stenting: Understanding and modeling the risk. Catheterization and Cardiovascular Interventions, 2020, 98, 246-254.	0.7	1
105	Incidence, treatment, and outcomes of acute myocardial infarction following transcatheter or surgical aortic valve replacement. Catheterization and Cardiovascular Interventions, 2021, , .	0.7	1
106	Intracoronary Ultrasound in Assessing Efficacy of Cardiovascular Drugs. Current Cardiovascular Imaging Reports, 2010, 3, 190-196.	0.4	0
107	Safety and Efficacy of Percutaneous Mitral Valve-in-Valve and Mitral Valve-in-Ring Procedures: Systematic Review and Pooled Analysis of 30 Day and One Year Outcomes. Structural Heart, 2018, 2, 421-430.	0.2	0
108	Unraveling the Cardiovascular PROSPECTs of Patients With Prediabetes. JACC: Cardiovascular Imaging, 2019, 12, 742-744.	2.3	0

#	Article	IF	CITATIONS
109	Lower TAVR Mortality Resulting from Collective and Coordinated Global Effort. Structural Heart, 2020, 4, 24-25.	0.2	0
110	Abstract 15526: Predictors of Elective Support Device Insertion Prior to High Risk Percutaneous Coronary Intervention: Changing Trends between 1993-2013. Circulation, 2014, 130, .	1.6	0
111	Abstract 18288: The Total-to-high Density Lipoprotein-cholesterol Ratio Associates With Coronary Atheroma Progression Rates and Reclassifies Disease Progression Across Populations With Varying Metabolic Risk. Circulation, 2015, 132, .	1.6	0
112	Devices to decrease stroke risk. Journal of Invasive Cardiology, 2004, 16, 54S-58S.	0.4	0